High <i>GPNMB</i> and <i>SPP1</i> expression is associated with worsened survival prognosis in human GBM patients.

<p>Data taken from the TCGA database, showing survival probability of glioma patients grouped according to high and low expression of our target genes <i>GPNMB</i> (A) and <i>SPP1</i> (B). High expression of both genes has a negative effect on patient prognosis. Patients were in addition grouped into the four molecular subtypes (proneural, neural, mesenchymal, and classical). Low <i>GPNMB</i> expression seems to have the most severe effect on patient prognosis in the proneural subtype when including G-CIMP⁺ tumors, but no significant effect in the other subtypes. Low <i>SPP1</i> expression seems to have the highest effect on patient prognosis in the neural and classical subtypes. Furthermore, both genes are differently regulated in the four subtypes (box plots in A and B) Significances for box plots: <i>GPNMB</i>: proneural GCIMP- (PG-) vs. proneural GCIMP+ (PG+) ***, PG- vs. mesenchymal (M) *** PG- vs. classical (C) **, PG+ vs. neural (N) ***, PG+ vs. M ***, PG+ vs. C **, N vs. M ***, N vs. C *, M vs. C ***. <i>SPP1</i>: PG- vs. M ***, PG+ vs. N ***, PG+ vs. M ***, C vs. M ***.*, p<0.05; **, p<0.01; ***, p<0.001